Last reviewed · How we verify
Metastatic non-small cell lung cancer
Approved treatments
- Retevmo · Eli Lilly
Retevmo works by blocking the activity of the RET protein, which is involved in the growth and spread of cancer cells. - Tabrecta · Novartis Pharm
Tabrecta works by blocking the hepatocyte growth factor receptor, a protein that helps cancer cells grow and spread. - Tecentriq · Roche
Tecentriq works by blocking a protein called PD-L1, which helps cancer cells hide from the immune system. - Gavreto · Rigel Pharms
Pralsetinib inhibits RET kinase and its oncogenic fusions/mutations, blocking downstream signaling and reducing tumor growth. - (CARBAMIDE®) · German University in Cairo
Clinical guidelines
- FDA label — 1L
IMFINZI in combination with tremelimumab-actl and platinum-based chemotherapy for the treatment of adult patients with metastatic NSCLC with no sensitizing EGFR mutations or ALK genomic tumor aberrations.
Competitive intelligence
For the full treatment-landscape CI brief — marketed leaders side-by-side, pipeline by phase, recent regulatory actions, sponsor landscape:
- Metastatic non-small cell lung cancer patent landscape — cliff calendar, originator estates, attackable patents
- Metastatic non-small cell lung cancer treatment landscape brief
- Metastatic non-small cell lung cancer treatment updates RSS
Frequently asked questions about Metastatic non-small cell lung cancer
What drugs treat Metastatic non-small cell lung cancer?
Tracked treatments include Retevmo, Tabrecta, Tecentriq, Gavreto, (CARBAMIDE®).
What is the treatment for Metastatic non-small cell lung cancer?
Standard treatment for Metastatic non-small cell lung cancer includes Retevmo, Tabrecta, Tecentriq, Gavreto, (CARBAMIDE®). See the treatment landscape page for first-line, second-line and salvage options.
What are the treatment guidelines for Metastatic non-small cell lung cancer?
FDA label publishes guidelines for Metastatic non-small cell lung cancer. 1 guideline references tracked.
Related
- Treatment landscape: Metastatic non-small cell lung cancer patent cliff · Metastatic non-small cell lung cancer CI report
- Treatment: Retevmo · Eli Lilly
- Treatment: Tabrecta · Novartis Pharm
- Treatment: Tecentriq · Roche
- Treatment: Gavreto · Rigel Pharms
- Treatment: (CARBAMIDE®) · German University in Cairo
- All diseases: Browse the disease index · Disease landscape hub
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing